$COO

COOPER COMPANIES, INC. (COO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 CooperCompanies Announces Leadership Transition and Board Refreshment Independent Director and Seasoned Healthcare Executive Walt Rosebrough Elected Executive Chair; Search for CEO Underway Provides Update on Board Refreshment, Including Planned Addition of Medical D

CooperCompanies (COO) announced Walt Rosebrough as Executive Chair, replacing Albert White III as CEO. Rosebrough, former STE CEO, will lead until a permanent replacement is found. The company also announced board changes and reaffirmed its fiscal 2026 guidance. White will serve as a strategic advisor until April 2027.

Neogen (NEOG) reported Q2 revenue of $222.8M, up 6.5% YoY, beating estimates. CooperCompanies (COO) reported flat revenue, missing expectations. Abbott (ABT) reported $12.59B revenue, up 13% YoY, beating estimates. Stryker (SYK) reported $6.59B revenue, up 9.4% YoY, meeting expectations. Stocks reacted accordingly to the results.

Piper Sandler maintained a Neutral rating on Cooper Companies (COO) with a $59 price target, citing uncertainty in its business outlook. The stock trades at $56.06, with a Fair Value estimate of $71.89. Analysts have revised earnings downward, and recent developments include a Q3 revenue miss and revised fiscal 2026 guidance. Multiple firms adjusted price targets and ratings, reflecting strategic challenges and weak sales.

CooperCompanies (COO) underperformed peers with weak results and guidance, stock down 14%. Baxter (BAX) beat estimates with 5.3% revenue growth, stock flat. Boston Scientific (BSX) missed guidance, stock down 6.2%. Abbott Labs (ABT) grew 13%, stock up 15.4%. Neogen (NEOG) beat estimates, stock down 2%. Market update discusses shifting investor concerns.

Cooper Companies (COO) opened The Vision Centre in England, a hub for R&D, clinical work, and manufacturing to accelerate contact lens product development. The centre integrates AI and data science, potentially speeding up product launches. Analysts expect $4.9B revenue and $782.6M earnings by 2029, with some forecasting lower figures due to potential pricing pressures and R&D costs.

The Cooper Companies (COO) director Lawrence Erik Kurzius bought 10,000 shares at $54.93 each, totaling $549,300. His total holdings now stand at 31,099 shares. The company reported $4.2B revenue and $570.3M net income over the past year. Kurzius also serves as CEO of McCormick & Co (MCK).

Stifel maintained a Buy rating on Cooper Companies (COO) with a $70 price target, citing competitive positioning and growth projections. The firm expects 3.1% growth for CooperVision by 2027 and mid-single-digit declines for Paragard. COO trades at a P/E of 19.67 and a PEG of 0.44, with a free cash flow yield above 7%. Recent earnings missed revenue expectations, leading to lowered guidance and mixed analyst reactions.

Jana Partners is pressuring The Cooper Companies (COO) to replace its CEO and board chair, and explore selling its CooperVision and CooperSurgical businesses, citing a 28% stock decline and operational issues. COO reported Q3 revenue of $1.07B, non-GAAP earnings up 4%, and free cash flow up 66% to $273M. Jana argues for leadership changes and potential asset sales, while critics point to flat revenue and inventory pressures.

CooperCompanies (COO) reported 1% revenue growth and 4% EPS increase in Q3. The company completed a strategic review, deciding to retain CooperSurgical and expand its share buyback program to $3 billion. Operational improvements and cost-cutting measures are planned. Institutional interest slightly increased, with BlackRock as the largest shareholder.